News - 2024
December 16, 2024 News
Oblique Therapeutics – Business Update
Oblique Therapeutics presents at Redeye
December 9, 2024 News
Oblique Therapeutics announces an agreement with leading animal health company
Oblique Therapeutics has entered into an agreement with a leading animal health company to apply the AbiProt® technology to generate antibodies to a high-value target.
August 22, 2024 News
Oblique Therapeutics enters a research agreement with Eli Lilly and Company
Stockholm, Sweden - August 22, 2024 - Oblique Therapeutics, a leading biotechnology company specialising in the development of new drug candidates, is pleased to announce that they have entered into a research collaboration agreement with Eli Lilly and Company (Lilly) to apply the AbiProt® technology to generate antibodies to a high-value target. This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties.
June 18, 2024 News
Oblique Therapeutics and KTH enters a strategic collaboration
Oblique Therapeutics and the KTH Royal Institute of Technology (KTH) have entered into a strategic collaboration to analyse protein structures using supercomputers
January 15, 2024 News
Oblique Therapeutics presents at Redeye
Oblique Therapeutics presents at Redeye